Provectus Biopharmaceuticals Inc
OTC:PVCT
Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. The company is headquartered in Knoxville, Tennessee and currently employs 4 full-time employees. The company went IPO on 2000-04-07. The firm is focused on developing immunotherapy medicines for different diseases, based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule, rose bengal sodium (RBS). Its product pipeline includes PV-10 and PH-10. Its PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP (current Good Manufacturing Practice) RBS, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBS, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. Its ongoing pre-clinical studies in other areas include hematology, virology, microbiology, ophthalmology, and animal health.
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. The company is headquartered in Knoxville, Tennessee and currently employs 4 full-time employees. The company went IPO on 2000-04-07. The firm is focused on developing immunotherapy medicines for different diseases, based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule, rose bengal sodium (RBS). Its product pipeline includes PV-10 and PH-10. Its PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP (current Good Manufacturing Practice) RBS, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBS, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. Its ongoing pre-clinical studies in other areas include hematology, virology, microbiology, ophthalmology, and animal health.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
